Drug intelligence / Profile preview

99mTc-EDDA-KL01099

Development stage
Unknown
Modality
Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

99mTc-EDDA-KL01099 is an experimental **PSMA-targeted radiopharmaceutical** imaging agent for prostate cancer detection by SPECT. It is a **technetium-99m-labeled small-molecule tracer** built on a Lys-urea-Glu PSMA-binding pharmacophore conjugated to a HYNIC chelator and formulated with EDDA as a co-ligand for technetium coordination. In preclinical studies, the tracer bound PSMA-expressing cells with nanomolar affinity and visualized PSMA-positive prostate cancer xenografts in SPECT imaging, but also showed relatively high renal and splenic uptake. Based on the provided literature context, it appears to be a research-stage academic radiotracer rather than a commercial product, investigated for molecular imaging of prostate cancer lesions.

Other names
technetium-99m EDDA-KL01099technetium99m EDDA-KL01099technetium 99m EDDA-KL0109999mTc-labeled KL01099
02

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on 99mTc-EDDA-KL01099.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 99mTc-EDDA-KL01099.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call